NasdaqGS:NTRABiotechs
Natera Expands MRD Ambitions With Latitude Study And AI NVIDIA Deal
Natera (NasdaqGS:NTRA) published validation data for its Latitude tissue free molecular residual disease assay in colorectal cancer.
The peer reviewed study reports high sensitivity and specificity for colorectal cancer detection and supports regulatory submissions.
Natera also announced new multimodal AI powered diagnostics that combine AI with pathology data for its Signatera MRD platform.
The company entered a collaboration with NVIDIA focused on accelerating AI model development and...